Medical Design Briefs - November 2022 - 10

2022 Create The Future Medical Honorable Mentions
sive measurements with a comfortable
band and an easy-to-use app will improve
compliance, thus providing
more effective care.
In volume, the devices can be manufactured
using roll-to-roll processes and
could be integrated into smartwatch
bands. The electronics costs will be similar
to low-end fitness bands, encouraging
adoption of PyrAmes' technology
across a broad range of applications.
The company's go-to-market strategy
is to launch products in multiple markets,
including noninvasive alternatives
to arterial lines, emergency medical
monitoring,
noninvasive
ambulatory
monitoring, and home health monitoring.
The first product for neonates is in
pilot production and a multi-site pivotal
validation study for 510(k) submission
to the FDA. Products for adult inpatient
and outpatient applications,
including home monitoring, are under
development.
A video of the technology is available at
https://www.youtube.com/watch?v=TZ
1kpAtYPg8.
Continuous Predictive Respiratory Monitoring
Richard Hughen, CEO
Ronen Feldman, CTO
Linshom Medical
L
inshom (which means to
breathe) is first to deliver continuous
predictive respiratory
monitoring to the patient
bedside and home. Compared
with current responsive systems used
today, this predictive respiratory device
eliminates the morbidity,
mortality, and cost associated
with unrecognized respiratory
compromise in healthcare.
The patented,
FDA-cleared
device provides an operating
room quality respiratory profile
including respiratory rate (RR),
tidal volume (TV), minute
ven tilation (MV), inspiratoryexpiratory
ratio (I/E), and apnea
detection, which are all delivered
continuously and in real
time.
Current technology is too
large, complex, and expensive
for the patient bedside or
home. Linshom is the only device,
outside of the OR and
ICU, capable of practically delivering
TV to the patient bedside.
TV is the volume of air
moved with each breath or the
quality of respiration. Respiratory
rate alone is inadequate to
predict respiratory decline, but
RR plus TV can predict respiratory
decline events 12-70 minutes prior
to an emergency.
going. Linshom's CPRM solves the
problem of unidentified respiratory
depression events (RDE) and can intercept
these catastrophic problems
before they occur and result in codes,
intensive care unit (ICU) transfers,
and sometimes death.
The value of continuous respiratory
monitoring has been proven and published
by Dartmouth demonstrating a
65 percent reduction in rapid redramatic.
However, this solution is not
deployed universally because the
equipment is large and expensive, and
training is intensive and not practically
deployable on a large scale. Linshom
has solved this with a small, inexpensive
respiratory sensor that can be
deployed on a large scale. Wide deployment
of an inexpensive sensor to
the patient bedside will save lives and
reduce morbidity and expense.
Unlike alternative technologies
(pulse oximetry and capnography),
the Linshom sensor
is not compromised by motion,
light, or supplemental oxygen
administration making it a robust
solution for respiratory
monitoring
during
medical
The device delivers continuous predictive respiratory monitoring to the
patient bedside and home.
sponse team deployment and a 48 percent
reduction in ICU transfers. This
The device enters a $1.9 billion
(U.S.) market via an IRB-approved
study in partnership with Brigham &
Women's Hospital (Harvard) in Q3
2022. Linshom holds issued patents
(in 10 countries) with new filings on10
resulted
in a $58,000 savings per patient
not transferred to the ICU and a
$1.5 million savings annually in a
small, 33 bed, orthopedic surgery
(hip, knee) unit. Extrapolated to more
(post-surgical) beds, the savings are
www.medicaldesignbriefs.com
evacuation (civilian or military).
There are 48 million operative
cases and 28 million ambulatory
surgery patient cases in
the United States annually.
These 76 million patients require
anesthesia and most have
no postoperative respiratory
monitoring post-surgery. This
translates to a $1.5 billion potential
market where $466 million
is served with the company's
first product (FDA cleared)
and $1.1 billion is served with
the second product. There are
137 million ER visits with 39 million
due to injury and 12 million
resulting in hospital admission.
Respiratory monitoring is
appropriate for ~half of this population
or a potential market of $1.3 billion
where $400 million is served with
the first product and $900 million with
the second.
A video of the technology is available
at https://www.youtube.comwatch?v=
QYzdAzfNXBI.
Medical Design Briefs, November 2022
https://www.youtube.com/watch?v=TZ1kpAtYPg8 https://www.youtube.com/watch?v=QYzdAzfNXBI http://www.medicaldesignbriefs.com
Medical Design Briefs - November 2022

Table of Contents for the Digital Edition of Medical Design Briefs - November 2022
